Catalent’s ProteoSuite Oral platform is designed for optimized selection of orally developable targeted protein degrader candidates.
Catalent’s ProteoSuite Oral platform is designed for optimized selection of orally developable targeted protein degrader (TPD) candidates for advancement into clinical trials. Factors considered by the platform include molecular descriptors, physicochemical characterizations, drug metabolism and pharmacokinetics data, and physiologically based pharmacokinetic modeling.
The ProteoSuite aims to improve the likelihood of oral TPD development success by utilizing specialized assays and developability models that systematically evaluate oral drug candidates and enable quick, effective shortlisting of potential candidates. The platform includes integrated potent handling capabilities from clinical development and supply to commercial.